Overview
Aralez Bio makes noncanonical amino acids (ncAAs) used in peptide drugs. It uses enzymes to produce these specialized amino acids more efficiently, at lower cost, and with less environmental impact, compared to traditional chemical synthesis. This method yields ncAAs at scale for pharmaceutical and biotech customers, including large drug companies and research labs. The product works as high-purity building blocks that researchers incorporate into peptides, small molecules, and drug conjugates to create new therapies. What sets Aralez Bio apart is its focus on a difficult, niche supply—the hard-to-make ncAAs—delivered through a scalable, enzyme-based process that reduces cost and supply chain risks. Its goal is to make ncAAs cheaper, greener, and easier to obtain so drug discovery and manufacturing can proceed faster and more reliably.
Work here?Claim your company
Simplify's take
What believers are saying
- Aralez expanded to hundreds of ncAAs during 2025 and 2026.
- June 2026 award and conference presence strengthen credibility with peptide-drug buyers.
- Tons-per-year manufacturing plans target commercial programs for large pharmaceutical customers.
What critics are saying
- Aralez last raised $12 million on October 29, 2024; scale-up needs more capital.
- Revenue depends on top-five pharma partnerships, creating concentration risk if one program slips.
- If rival routes beat enzymatic costs by 2027, Aralez’s ncAA moat collapses.
What makes Aralez Bio unique
- Aralez Bio’s enzymatic ncAA platform won ACS GCIPR’s 2026 Green Chemistry Award.
- June 2026 data shows kilogram-scale runs and 20–50 kg batches for key targets.
- The company claims water-based, single-step synthesis cuts waste and emissions 99%.
Help us improve and share your feedback! Did you find this helpful?